For the second time in two years Alexion Pharmaceuticals has run afoul of FDA inspectors who cited the drug maker for lax manufacturing practices at a plant that makes its only marketed product the pricey Soliris treatment for combating a rare blood disorder The agency cited the drug maker for three production issues found during an inspection this month and these were separate from problems cited in a March  warning letter that followed an earlier inspection in  according to a filing with the US Securities and Exchange Commission